AOD-9604
Anti-Obesity Drug 9604 (Tyr-hGH 177-191)
Not FDA-approved. Was previously on the FDA Category 2 compounding restrictions list but was removed in late 2024 following nomination withdrawal. The main clinical trial for obesity failed its primary endpoint.
A lab-made fragment of growth hormone designed to stimulate fat burning without the growth-promoting or blood-sugar effects of full growth hormone. Six human trials involving about 900 people were conducted, but the main 24-week trial did not show meaningful fat loss and development was discontinued in 2007.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
AOD-9604 has moderate clinical evidence but is not FDA-approved.
Not FDA-approved. Was previously on the FDA Category 2 compounding restrictions list but was removed in late 2024 following nomination withdrawal. The main clinical trial for obesity failed its primary endpoint.
Safety Summary
Across six randomized, double-blind, placebo-controlled trials (approximately 900 subjects), the overall adverse event profile of AOD-9604 was indistinguishable from placebo (Stier et al. 2013, J Endocrinol Metab). In the largest trial (METAOD006, n=536), any adverse event occurred in 78.7% of AOD-9604 vs 83.2% of placebo groups -- slightly lower in the treatment group. The most frequently reported events were nasopharyngitis/infections (46.8% vs 17.5% pre-treatment baseline), headache (30.1% vs 25.9% placebo), musculoskeletal complaints (25.5% vs 8.2% placebo), and GI disorders (22.9% vs 7.8% placebo), though none were definitively attributed to treatment. No anti-AOD-9604 antibodies were detected. No effects on IGF-1, glucose tolerance, or insulin sensitivity were observed. No clinically significant changes in lab parameters, vital signs, or ECGs were found (Stier et al. 2013). These safety data come from oral administration programs; long-term safety for community subcutaneous injection protocols has not been formally established. The main criticism of AOD-9604 is efficacy rather than safety.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 13 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 11146367PubMed
- 2PMID 11673763PubMed
- 3PMID 11713213PubMed
- 4PMID 23092275PubMed
- 5Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans.Reference
- 6Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health.Reference
- 7PMID 25208511PubMed
- 8PMID 26275694PubMed
- 9PMID 24906629PubMed
- 10PMID 35783198PubMed
- 11PMID 41490200PubMed
- 12doi:10.1177/19476035241276406DOI
- 13PMID 15134286PubMed